Streetbeat News

Price Targets

LBTYA

UBS analyst Polo Tang has maintained a 'Buy' rating on Liberty Global (NASDAQ:LBTYA) but lowered the price target from $25 to $24.5.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 4:00 pm

JCI

UBS analyst Markus Mittermaier maintains a 'Buy' rating on Johnson Controls Intl (NYSE:JCI) but lowers the price target from $80 to $74.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 3:58 pm

GM

UBS analyst Patrick Hummel has maintained a 'Buy' rating on General Motors (NYSE:GM) but lowered the price target from $44 to $43.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 3:57 pm

DVN

UBS analyst Josh Silverstein has maintained a Neutral rating on Devon Energy (NYSE:DVN) and lowered the price target from $55 to $54.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 3:56 pm

BLDP

UBS analyst Manav Gupta has maintained a Neutral rating on Ballard Power Systems (NASDAQ:BLDP) and lowered the price target from $6.5 to $4.25.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 3:55 pm

PYPL

A significant amount of unusual options activity has been observed for PayPal Holdings (NASDAQ:PYPL), indicating a bullish stance by a large investor or institution. The overall sentiment of these big-money traders is split between 52% bullish and 47% bearish. The price target for PayPal Holdings over the last 3 months has been between $50.0 to $75.0. Analysts have mixed ratings on the stock, with some maintaining their ratings and others downgrading.

Portfolio Pulse from Benzinga Insights

October 10, 2023 | 3:45 pm

RARE

Morgan Stanley analyst Jeffrey Hung has maintained an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) but lowered the price target from $95 to $90.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 3:26 pm

RYTM

Morgan Stanley analyst Jeffrey Hung has maintained an Equal-Weight rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and raised the price target from $28 to $29.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 3:24 pm

FOLD

Morgan Stanley analyst Andrew Galler has maintained an Equal-Weight rating on Amicus Therapeutics (NASDAQ:FOLD) and lowered the price target from $15 to $14.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 3:17 pm

ALNY

Morgan Stanley analyst Michael Ulz has maintained an Equal-Weight rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and lowered the price target from $210 to $175.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 3:16 pm